|
2025
|
Invention
|
Method of treating major depressive disorder.
The present invention provides a method for safe a... |
|
2024
|
Invention
|
Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive diso... |
|
|
Invention
|
Method of treating major depressive disorder.
The present disclosure provides methods for safe a... |
|
|
Invention
|
Dosage regime with esketamine for treating major depressive disorder.
The present disclosure pro... |
|
2023
|
Invention
|
Method of treating major depressive disorder. The present invention provides a method for safe an... |
|
|
Invention
|
Methods of treating pruritus. The present disclosure related to methods of treating pruritus in a... |
|
|
Invention
|
Topical detomidine formulations.
The present disclosure relates to a purified detomidine HCl pha... |
|
|
Invention
|
Immediate release abuse-deterrent granulated dosage forms.
Described are immediate release oral ... |
|
|
Invention
|
Dosage regime with esketamine for treating major depressive disorder. The present disclosure prov... |
|
|
Invention
|
Abuse-deterrent dosage forms containing esketamine. Disclosed herein are immediate release oral d... |
|
|
Invention
|
Topical detomidine formulations.
Disclosed herein are topical formulations comprising about 0.00... |
|
2022
|
Invention
|
Long acting gastric residence system. Provided herein are gastroretentive dosage forms (GRDFs) fo... |
|
|
Invention
|
Gastric residence system.
The present disclosure is in the field of gastric resident systems. A ... |
|
|
Invention
|
Method of treating parkinson's disease.
The disclosure is directed to methods of treating Parkin... |
|
|
Invention
|
Method of treating parkinson's disease. The disclosure is directed to methods of treating Parkins... |
|
|
Invention
|
Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease.
Provi... |
|
|
Invention
|
Gastroretentive devices for assessment of intragastric conditions. Provided are gastroretentive d... |
|
2021
|
Invention
|
Immediate release abuse-deterrent granulated dosage forms. Described are immediate release oral d... |
|
|
Invention
|
Abuse-deterrent dosage forms containing esketamine.
Disclosed herein are immediate release oral ... |
|
|
Invention
|
Expandable gastroretentive dosage form.
An oral gastro-retentive delivery device is provided whi... |
|
|
Invention
|
Finished fibrous structures and methods of their use and preparation.
The disclosure is directed... |
|
|
Invention
|
Gastric retentive devices.
Provided are devices that are configured for gastric retention for a ... |
|
2020
|
Invention
|
Method of treating conditions.
The present invention provides a method for safe and efficacious ... |
|
|
Invention
|
Dosage regime with esketamine for treating major depressive disorder. The present invention provi... |
|
|
Invention
|
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions.
The pres... |
|
|
Invention
|
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions. The prese... |
|
|
Invention
|
Method of treating post-traumatic stress syndrome.
The present disclosure provides methods for s... |
|
|
Invention
|
Dosage forms for preventing drug-facilitated assault.
Disclosed herein are immediate release ora... |
|
|
Invention
|
Finished fibrous sructures and methods of their use and preparation.
The invention is directed t... |
|
|
Invention
|
Methods of treating pruritus.
The present disclosure related to methods of treating pruritus in ... |
|
2019
|
Invention
|
Esketamine for use in treating major depressive disorder. The present invention provides a dosage... |
|
|
Invention
|
Purified detomidine, process of preparing and methods of use.
The present disclosure relates to ... |
|
|
P/S
|
Pharmaceutical preparations, medications and veterinary
preparations for sustained and controlle... |
|
|
P/S
|
Pharmaceutical preparations, medications and veterinary preparations, namely, drug delivery agent... |
|
2018
|
Invention
|
Long acting gastric residence system. The present disclosure is in the field of gastroretentive d... |
|
|
P/S
|
Pharmaceutical and medical preparations for the treatment of genetic, cardiovascular, central ner... |
|
|
P/S
|
Pharmaceutical and medical preparations for the treatment of
genetic, cardiovascular, central ne... |
